Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Paliperidone (Trevicta®)		Third line option Patient has been stable mentally for at least 12 months and had a stable dose of paliperidone palmitate monthly injection and has not required a dosage adjustment in the last six months 12 months using the monthly injections and no dose adjustment for the last six months before considering the three-monthly injection APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion)
Paliperidone (Xeplion®)		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
Panitumumab concentrate for infusion	TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy	Negative TA
Paracetamol soluble tablets		High sodium content - only if swallowing difficulties.
Paraffin yellow soft BP		CCU/ITU use
Paramomycin for trichomonas vaginalis		For trichomonas vaginalis
Parenteral nutrition (TPN or PN)		Parenteral Nutrition (TPN or PN). TPN scratch bag. All patients who require parenteral nutrition must be referred to the Parenteral Nutrition Team. For patients who require home care, arrangements for discharge must be made as early as possible. Basic regimes are stocked for emergencies but wherever possible treatment must be tailored to the needs of the patient. These regimens are required to be ordered specially and may take a few days to arrive.
Patiromer (Veltassa®)	TA623 - Patriomer for treating hyperkalaemia	In emergency care for acute life-threatening hyperkalaemia alongside standard care
Patiromer (Veltassa®)	TA623: Patiromer for treating hyperkalaemia	RICaD: Patiromer for treating hyperkalaemia
Pediacel		Supported with PGD

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.